#regeneron

[ follow ]
#23andme #bankruptcy #data-privacy #genetic-testing #genetic-data #acquisition #biotechnology #eylea #biosimilars
#23andme
fromTechCrunch
9 months ago
EU data protection

23andMe says 15% of customers asked to delete their genetic data since bankruptcy | TechCrunch

fromZDNET
10 months ago
Privacy technologies

A drug developer is buying 23andMe - what does that mean for your DNA data?

Marketing tech
fromFast Company
10 months ago

23andMe, including sensitive genetic data, sold to biotech company Regeneron Pharmaceuticals

Regeneron Pharmaceuticals has acquired 23andMe for $256 million, committing to uphold privacy standards for sensitive genetic data.
NYC startup
fromThe Verge
10 months ago

23andMe and its user data will soon belong to a pharmaceutical giant

23andMe will continue its DNA testing services following acquisition by Regeneron Pharmaceuticals, ensuring privacy protections and customer data management remain in place.
fromTechCrunch
9 months ago
EU data protection

23andMe says 15% of customers asked to delete their genetic data since bankruptcy | TechCrunch

Privacy technologies
fromZDNET
10 months ago

A drug developer is buying 23andMe - what does that mean for your DNA data?

23andMe is being acquired by Regeneron after a data breach and bankruptcy, ensuring continued operations while aiming to secure customer data.
Marketing tech
fromFast Company
10 months ago

23andMe, including sensitive genetic data, sold to biotech company Regeneron Pharmaceuticals

Regeneron Pharmaceuticals has acquired 23andMe for $256 million, committing to uphold privacy standards for sensitive genetic data.
NYC startup
fromThe Verge
10 months ago

23andMe and its user data will soon belong to a pharmaceutical giant

23andMe will continue its DNA testing services following acquisition by Regeneron Pharmaceuticals, ensuring privacy protections and customer data management remain in place.
more#23andme
Marketing tech
fromMedCity News
10 months ago

23andMe Bankruptcy Auction Win Adds Big Piece to Regeneron's Gene-Based Drug R&D Efforts - MedCity News

Regeneron enhances genetic research capabilities with $256M acquisition of 23andMe assets.
[ Load more ]